Abbott

30,560.00
+230.00
(0.76%)
Market Cap
64,449.10 Cr
EPS
565.30
PE Ratio
48.36
Dividend Yield
1.35 %
Industry
Healthcare
52 Week High
31,898.95
52 Week Low
25,325.00
PB Ratio
18.33
Debt to Equity
0.03
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from5 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Abbott India Ltd: Q4 Profit and Revenue Surge, Stock ClimbsToday
Abbott India Ltd reported a 14.7% increase in Q4 net profit to Rs 359 crore, surpassing estimates. Revenue rose 9% to Rs 1,633 crore, while EBITDA grew 15% to Rs 439 crore. The company's stock price gained nearly 4%, reaching Rs 31,500 per share.
positive
Abbott India Reports Q4 Results and Recommends DividendToday
Abbott India has reported its quarterly results. The company's Q4 net profit increased to 3.7 billion rupees, up from 2.87 billion rupees year-over-year and 3.6 billion rupees quarter-over-quarter. Q4 revenue rose to 16 billion rupees from 14.39 billion rupees year-over-year. Additionally, the company has recommended a dividend of 475 rupees per equity share.
positive
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed22 hours ago
Abbott India reported a 27.9% YoY increase in Q4 net profit to ₹367 crore. Revenue grew 11.5% to ₹1,604.6 crore. EBITDA rose 30% with margin expanding to 26.7%. The board recommended a final dividend of ₹475 per share for FY25, subject to shareholder approval.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,734.90
#1 4,17,508.30
35.39
#1 49,887.20
12.06
#1 9,648
13.77
47.70
6,279.50
1,64,975.40
79.75
8,184.00
0.89
1,600
64.53
62.83
1,499.90
1,21,319.90
23.01
26,520.70
14.17
4,155
30.28
49.42
3,266.80
1,10,502.40
59.35
10,785.70
11.59
1,656
13.54
52.85
2,572.70
1,05,616.00
51.74
10,615.60
19.57
1,942
-16.38
59.84
1,230.70
1,03,163.70
#1 18.22
28,905.40
12.36
5,578
21.14
64.04
2,068.40
94,636.40
28.82
20,141.50
#1 19.94
1,936
#1 112.49
52.76
902.70
91,034.00
20.07
19,831.50
13.82
3,831
29.92
56.61
1,201.20
70,677.70
20.05
29,559.20
17.55
3,169
-10.04
51.74
30,560.00
#10 64,449.10
#7 48.36
#10 6,097.20
#9 10.80
#10 1,201
#5 27.83
54.55
Forecast
Actual
Growth Rate
Revenue Growth
10.80 %
Net Income Growth
26.52 %
Cash Flow Change
35.75 %
ROE
9.07 %
ROCE
9.92 %
EBITDA Margin (Avg.)
12.91 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
2,337
2,665
2,960
3,416
3,792
4,208
4,391
4,997
5,503
6,097
6,685
Expenses
1,977
2,250
2,505
2,774
3,074
3,337
3,389
3,832
4,143
4,396
4,715
EBITDA
360
415
455
642
718
871
1,002
1,165
1,360
1,701
1,970
Operating Profit %
13 %
14 %
14 %
16 %
16 %
18 %
21 %
22 %
23 %
25 %
26 %
Depreciation
15
14
16
16
17
60
58
66
70
71
72
Interest
1
3
2
4
2
9
18
19
16
12
12
Profit Before Tax
344
398
437
622
699
803
926
1,080
1,274
1,618
1,887
Tax
115
143
160
220
249
210
235
281
324
417
470
Net Profit
229
255
277
401
450
593
691
799
949
1,201
1,414
EPS in ₹
107.75
120.12
130.19
188.81
211.93
279.04
325.04
375.87
446.80
565.30
665.60

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
Fixed Assets
96
109
110
81
105
270
251
271
237
225
Current Assets
1,226
1,451
1,893
2,266
2,761
3,205
3,487
3,853
3,025
3,246
Capital Work in Progress
4
3
6
2
1
2
1
1
4
10
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
1,274
1,505
1,950
2,333
2,835
3,275
3,589
3,953
4,315
4,958
Total Liabilities
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
Current Liabilities
397
382
632
668
857
891
1,031
1,203
1,206
1,343
Non Current Liabilities
39
39
47
55
75
224
207
201
161
152
Total Equity
938
1,196
1,387
1,693
2,009
2,432
2,602
2,820
3,189
3,699
Reserve & Surplus
916
1,174
1,366
1,672
1,987
2,410
2,581
2,799
3,167
3,678
Share Capital
21
21
21
21
21
21
21
21
21
21

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-30
91
62
-165
99
8
73
-86
107
52
Investing Activities
-187
-77
-155
-215
-257
-401
-72
-396
-148
-416
Operating Activities
215
249
307
153
499
626
727
948
893
1,213
Financing Activities
-58
-80
-90
-102
-143
-217
-582
-637
-639
-745

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.18 %
0.18 %
0.18 %
0.16 %
0.16 %
0.16 %
DIIs
4.60 %
5.80 %
4.30 %
4.20 %
4.96 %
5.24 %
7.73 %
8.39 %
8.62 %
8.67 %
8.71 %
8.74 %
8.91 %
8.81 %
8.99 %
9.01 %
8.92 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.15 %
15.83 %
15.60 %
15.81 %
15.15 %
14.72 %
14.60 %
14.25 %
14.07 %
13.95 %
13.89 %
13.97 %
13.80 %
13.86 %
13.65 %
13.59 %
13.66 %
Others
4.26 %
3.38 %
5.11 %
5.01 %
4.91 %
5.06 %
2.68 %
2.37 %
2.32 %
2.39 %
2.42 %
2.13 %
2.12 %
2.16 %
2.21 %
2.25 %
2.28 %
No of Share Holders
0
84,478
75,540
73,417
83,236
90,567
82,113
83,526
72,086
69,582
68,885
72,252
69,382
71,588
69,449
67,892
69,934

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 40 55 65 250 275 275 325 410 0.00
Dividend Yield (%) 0.00 0.73 0.75 0.42 1.67 1.55 1.26 1.2 1.33 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 30,145.75 30,348.45
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Feb 2025 26,518.15 26,142.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 28,526.15 29,115.20
08 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2024 25,945.60 28,136.85
19 Jul 2024 DIVIDEND Dividend
410.00 /share
19 Jul 2024 25,945.60 28,795.65
21 Jul 2023 DIVIDEND Dividend
145.00 /share
21 Jul 2023 20,970.55 23,665.10
21 Jul 2023 DIVIDEND Dividend
180.00 /share
21 Jul 2023 20,970.55 23,665.10
04 Aug 2022 DIVIDEND Dividend
130.00 /share
02 Aug 2022 16,529.20 20,621.45
04 Aug 2022 DIVIDEND Dividend
145.00 /share
02 Aug 2022 16,529.20 20,621.45
21 Jul 2021 DIVIDEND Dividend
155.00 /share
19 Jul 2021 16,224.75 17,427.95
21 Jul 2021 DIVIDEND Dividend
120.00 /share
19 Jul 2021 16,224.75 17,427.95

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 hours ago
Record Date For Entitlement Of Dividend23 hours ago
Annual General Meeting On August 13 202523 hours ago
Announcement under Regulation 30 (LODR)-Dividend Updates23 hours ago
Results For The Financial Year Ended March 31 202523 hours ago
Board Meeting Outcome for Outcome Of Board Meeting1 day ago
Announcement under Regulation 30 (LODR)-Change in Management9 days ago
Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.9 days ago
Announcement Under Regulation 30.Apr 30, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Closure of Trading WindowMar 25, 2025
Rumour verification - Regulation 30(11)Mar 06, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Integrated Filing (Financial)Feb 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.Jan 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 03, 2025
Closure of Trading WindowDec 23, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorDec 16, 2024
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Dec 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Abbott Launches 14 Valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection For Children Against Pneumococcal Bacterial Infections.Nov 28, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India ( Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Related Party Transaction Statement For The Half Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 07, 2024
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 07, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 05, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 31, 2024
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 28, 2024

Technical Indicators

RSI(14)
Neutral
51.70
ATR(14)
Volatile
726.20
STOCH(9,6)
Neutral
48.09
STOCH RSI(14)
Neutral
56.53
MACD(12,26)
Bearish
-3.70
ADX(14)
Weak Trend
10.93
UO(9)
Bearish
39.54
ROC(12)
Uptrend But Slowing Down
0.76
WillR(14)
Neutral
-57.07

About Abbott

Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Chairperson NameMunir Shaikh